Chew On This: FDA OK's King's Tamper-Resistant Morphine, Embeda
This article was originally published in The Pink Sheet Daily
Executive Summary
Embeda to launch in September backed by 610 sales reps, Chief Commercial Officer Andrzejewski says.
You may also be interested in...
REMS For Individual Opioids Show FDA Flexibility, Keep Class Options Open
As FDA works with stakeholders on a class-wide Risk Evaluation and Mitigation Strategy for long-acting and extended-release opioids, the REMS that have been approved for individual opioid products indicate agency flexibility in addressing risk management, according to Edgar Adams, executive director of epidemiology at Covance
REMS For Individual Opioids Show FDA Flexibility, Keep Class Options Open
As FDA works with stakeholders on a class-wide Risk Evaluation and Mitigation Strategy for long-acting and extended-release opioids, the REMS that have been approved for individual opioid products indicate agency flexibility in addressing risk management, according to Edgar Adams, executive director of epidemiology at Covance
FDA Okays Purdue's Newer OxyContin; Payors And Physicians Chew On Drug's Benefit
Purdue's reformulated OxyContin could face generics in 2013 unless FDA withdraws the initial NDA because of safety concerns.